Skip to main content
Premium Trial:

Request an Annual Quote

Quark, Biocon to Collaborate on RNAi Drug Development in India

Premium

Quark Pharmaceuticals and Indian biotech firm Biocon announced this week that they have formed a partnership to develop and market siRNA-based drugs.

Under the deal, Biocon will have access to Quark's RNAi technology and knowhow to create novel drugs for the Indian market, as well as certain other undisclosed territories.

Biocon will also be able to co-develop and sell Quark's investigational glaucoma treatment QPI-1007 in those areas. The drug recently completed a phase I/IIa trial in a related condition called non-arteritic anterior ischemic optic neuropathy.

Additional terms of the arrangement were not disclosed.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.